Pathophysiology of CNV is characterized by vascular endothelial growth factor (VEGF) mediated choroidal vascular endothelial cell (CVECs) proliferation, a potential target for antivascular endothelial growth factor therapy (anti-VEGF) [3].In the past, CNV associated with AMD was treated by transferring thermal energy to the proliferating CVECs with conventional or modified laser (photodynamic therapy) [4]. The gene discussed is VEGFA; the disease is age-related macular degeneration.